16:51 , Apr 2, 2018 |  BioCentury  |  Finance

Maintaining Moderna

A rumored dual listing on the Hong Kong stock exchange and NASDAQ could enable Moderna Therapeutics Inc. to maintain its ballooning valuation as it enters the public market. The mRNA play has raised $1.6 billion...
20:13 , Feb 9, 2018 |  BC Week In Review  |  Financial News

mRNA company Moderna raises $500M series G

Moderna Therapeutics Inc. (Cambridge, Mass.) raised $500 million in an untranched series G round on Feb. 1. New investors included an Abu Dhabi Investment Authority subsidiary, BB Biotech AG (SIX:BION; Xetra:BBZA), Julius Baer, EDBI and...
22:07 , Feb 2, 2018 |  BioCentury  |  Finance

Private ambition

BB Biotech AG (SIX:BION; Xetra:BBZA) made a rare private investment in Moderna Therapeutics Inc.’s $500 million series G round and wants to see clinical proof-of-concept data from at least one rare liver disease asset before...
21:29 , Feb 1, 2018 |  BC Extra  |  Financial News

mRNA play Moderna raises $500M series G

Moderna Therapeutics Inc. (Cambridge, Mass.) raised $500 million in an untranched series G round. New investors included an Abu Dhabi Investment Authority subsidiary, BB Biotech AG (SIX:BION; Xetra:BBZA), Julius Baer, EDBI and Sequoia Capital China....
16:38 , Jan 12, 2018 |  BC Week In Review  |  Company News

Moderna advances pipeline with Phase II of AZD-8601

Moderna Therapeutics Inc. (Cambridge, Mass.) said AZD-8601 will be its first program to advance into Phase II testing. This quarter, the company plans to begin a Phase IIa trial of the candidate, which is partnered...
01:10 , Jan 10, 2018 |  BC Extra  |  Company News

Moderna advances pipeline with Phase II of AZD-8601

Moderna Therapeutics Inc. (Cambridge, Mass.) said AZD-8601 will be its first program to advance into Phase II testing. This quarter, the company plans to begin a Phase IIa trial of the candidate, which is partnered...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

Moderna unveils organizational changes and new candidates

Moderna Therapeutics Inc. (Cambridge, Mass.) said its CBO, Saqib Islam, plans to leave the company in September "to pursue other opportunities." Meanwhile, the company is undergoing organizational restructuring of its business model. Moderna said it will...
22:35 , Sep 14, 2017 |  BC Extra  |  Company News

Moderna unveils organizational changes and new candidates

Moderna Therapeutics Inc. (Cambridge, Mass.) said its CBO, Saqib Islam, plans to leave the company in September "to pursue other opportunities." Meanwhile, the company is undergoing organizational restructuring of its business model. Moderna said it will...
23:43 , Aug 21, 2017 |  BC Extra  |  Company News

ethris and AZ partner to develop respiratory mRNA therapies

ethris GmbH (Martinsried, Germany) partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit to develop mRNA therapies for respiratory diseases using ethris' stabilized non-immunogenic messenger RNA (SNIM-RNA) technology. ethris will receive €25 million...
01:44 , Feb 25, 2017 |  BioCentury  |  Product Development

Getting the message

Hailed as a faster, cheaper way of producing therapeutic proteins than recombinant technologies, mRNA technologies have attracted some $2.5 billion from partnerships and investments from pharmas and VCs hoping to get in on the ground...